Mepolizumab
Nucala (mepolizumab) is an antibody pharmaceutical. Mepolizumab was first approved as Nucala on 2015-11-04. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.
| Trade Name | Nucala |
|---|---|
| Common Name | Mepolizumab |
| Indication | asthma |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
